J&J's Van Hoof Talks About Expanding Vaccines Development
A pair of technology platforms acquired in the 2010 buyout of Crucell is enabling J&J to produce higher yields of vaccines and deliver safely using adenovirus vectors.
A pair of technology platforms acquired in the 2010 buyout of Crucell is enabling J&J to produce higher yields of vaccines and deliver safely using adenovirus vectors.